30 closest matches · ranked by relevance
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
Healthy
Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001
Middle East Respiratory Syndrome Coronavirus
Primary: Number of Participants Having Adverse Events — 1; 2; 2; 4 Participants
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
COVID-19
Primary: Improvement in Oxygenation — 25.7; 29.7 ratio
SARS (Severe Acute Respiratory Syndrome) · Coronavirus
Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
MERS (Middle East Respiratory Syndrome)
Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Respiratory Distress Syndrome, Adult
Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants
SARS-CoV Infection
Primary: Mechanical Ventilation — 1; 1 Participants
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
Respiratory Disorders
Primary: Percentage of Sputum Samples Positive for Bacterial Pathogens as Identified by Bacteriological Methods, in Any Stable COPD Patients and During AECOPDs — 74.2; 78; 94.6…
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Corona Virus Infection
Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by Protocol Definition of AE — 3; 0; 0; 1 Participants
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
COVID-19
Primary: Sambucol Reduces the Severity of Symptoms by at Least 30% by Day 10 in People Who Are Symptomatic With the SARS-CoV-2 (COVID-19) Virus, Compared to Placebo. — 84.3; 86.5…
COVID-19 Pneumonia, Impaired Respiratory Function
Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 14.5; 13.5 Score on a scale — p=0.33
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
ARDS · Mechanical Ventilation Complication · Ventilator-Induced Lung Injury
Primary: Number of Participants Who Survived and Died — 1; 31; 14; 19 Participants
Sepsis
Primary: Mortality — 11 Participants
Corona Virus Infection
Primary: Number of Patients With Any TEAEs During the Treatment Period Baseline to Day 14 — 5; 10 Participants
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…